SESN Stock Overview
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer.
Notes are coming soon
Sesen Bio, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.61|
|52 Week High||US$0.96|
|52 Week Low||US$0.36|
|1 Month Change||0.082%|
|3 Month Change||11.87%|
|1 Year Change||-16.68%|
|3 Year Change||-32.97%|
|5 Year Change||-28.74%|
|Change since IPO||-94.38%|
Recent News & Updates
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth CarefullyApr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn RateDec 05
Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00Aug 12
News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under ThreatFeb 18
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?Jan 26
Sesen Bio, Inc.'s (NASDAQ:SESN) Profit OutlookDec 21
|SESN||US Biotechs||US Market|
Return vs Industry: SESN underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: SESN underperformed the US Market which returned -9.2% over the past year.
|SESN Average Weekly Movement||7.3%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: SESN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SESN's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent.
Sesen Bio, Inc. Fundamentals Summary
|SESN fundamental statistics|
Is SESN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SESN income statement (TTM)|
|Cost of Revenue||US$25.31m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.017|
|Net Profit Margin||-5.61%|
How did SESN perform over the long term?See historical performance and comparison